A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy
Phase of Trial: Phase III
Latest Information Update: 13 Aug 2018
At a glance
- Drugs Risankizumab (Primary) ; Secukinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 18 May 2018 Planned End Date changed from 27 May 2020 to 25 Jun 2020.
- 18 May 2018 Status changed from not yet recruiting to recruiting.
- 29 Mar 2018 New trial record